Wearable Heart Patch Checks for Hidden Atrial Fibrillation After Stroke
Tests a wearable heart patch to detect atrial fibrillation in people with unexplained stroke.
Plain-language title generated from the registry record
Registry title: Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Asan Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Asan Medical Center
- Trial code
- NCT07295769
- Record updated
- 6 February 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of a wearable device in detecting previously undiagnosed atrial fibrillation through non-invasive long-term monitoring using a wearable single-lead ECG patch (MEMO Patch M, MEMO Patch2) in 100 patients with Embolic Stroke of Undetermined Source (ESUS) who require atrial fibrillation screening. Participants who meet all inclusion and exclusion criteria and provide written informed consent will wear the MEMO Patch M and undergo in-hospital telemetry monitoring using MEMO Cue for a minimum of 12 hours and up to 8 days. During hospitalization, 24-hour Holter monitoring will also be conducted. Before discharge, the investigator will review these results to determine whether implantable loop recorder (ILR) implantation is necessary. At the time of discharge, participants will wear MEMO Patch2 for up to 14 days for the first ECG monitoring period. One month after discharge, the investigator will review the results of the first monitoring and initiate the second ECG monitoring with MEMO Patch2. Three months after discharge, the results of the second ECG monitoring will be reviewed, and participation in the clinical trial will be completed.Read full original descriptionShow less
Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause: A Single-Center, Prospective, Exploratory Trial to Validate the Efficacy and Safety of Noninvasive Long-Term Electrocardiographic Monitoring
The purpose of this study is to evaluate the efficacy and safety of a wearable device in detecting previously undiagnosed atrial fibrillation through non-invasive long-term monitoring using a wearable single-lead ECG patch (MEMO Patch M, MEMO Patch2) in 100 patients with Embolic Stroke of Undetermined Source (ESUS) who require atrial fibrillation screening. Participants who meet all inclusion and exclusion criteria and provide written informed consent will wear the MEMO Patch M and undergo in-hospital telemetry monitoring using MEMO Cue for a minimum of 12 hours and up to 8 days. During hospitalization, 24-hour Holter monitoring will also be conducted. Before discharge, the investigator will review these results to determine whether implantable loop recorder (ILR) implantation is necessary. At the time of discharge, participants will wear MEMO Patch2 for up to 14 days for the first ECG monitoring period. One month after discharge, the investigator will review the results of the first monitoring and initiate the second ECG monitoring with MEMO Patch2. Three months after discharge, the results of the second ECG monitoring will be reviewed, and participation in the clinical trial will be completed.
Inclusion: Participants may take part in this clinical study only if they meet all of the following criteria:; Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study; Patients diagnosed with ESUS (Embolic Stroke of Undetermined Source); Patients who require in-hospital or out-of-hospital electrocardiographic (ECG) monitoring.
Exclusion: Individuals with a clearly identified cause of stroke; Individuals known to have allergic reactions to adhesives or hydrogels; Participants who meet any of the following criteria cannot be enrolled in this clinical study:; Individuals already diagnosed with atrial fibrillation or atrial flutter; Individuals who, in the investigator's judgment, have cognitive vulnerability that makes it difficult to understand the study information and voluntarily decide on participation; Any other individuals whom the principal investigator considers to be at potential risk by participating in the study or otherwise unsuitable for participation.